Cost‐Effectiveness Analyses Throughout the Drug Development Life Cycle
作者： Renée J.G. Arnold
DOI: 10.1002/0471266949.BMC161
关键词:
摘要: Cost-effectiveness analysis (CEA) is a systematic, quantitative method for summarizing health benefits and resources of various treatment options into single numbers or ratios so that policy makers can choose among them. Computer modeling cost-effectiveness may play significant role in informing the pharmaceutical decision-making process throughout product's life cycle, increasing likelihood reimbursement broad use. Keywords: cost-effectiveness; decision analysis; economics; modeling
sci-hub.se 参考文章(22)
Gillian D. Sanders, Al V. Taira, Cost Effectiveness of a Potential Vaccine for Human papillomavirus Emerging Infectious Diseases. ,vol. 9, pp. 37- 48 ,(2003) , 10.3201/EID0901.020168
Shalini L. Kulasingam, Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs JAMA. ,vol. 290, pp. 781- 789 ,(2003) , 10.1001/JAMA.290.6.781
Marc Brisson, Nicolas Van de Velde, Philippe De Wals, Marie-Claude Boily, The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine. ,vol. 25, pp. 5399- 5408 ,(2007) , 10.1016/J.VACCINE.2007.04.086
Luciano Caprino, Pierluigi Russo, Developing a paradigm of drug innovation: an evaluation algorithm. Drug Discovery Today. ,vol. 11, pp. 999- 1006 ,(2006) , 10.1016/J.DRUDIS.2006.09.009
Robert M. Califf, Defining The Balance Of Risk And Benefit In The Era Of Genomics And Proteomics Health Affairs. ,vol. 23, pp. 77- 87 ,(2004) , 10.1377/HLTHAFF.23.1.77
John A. Vernon, W. Keener Hughen, Scott J. Johnson, Mathematical modeling and pharmaceutical pricing: analyses used to inform in-licensing and developmental go/No-Go decisions. Health Care Management Science. ,vol. 8, pp. 167- 179 ,(2005) , 10.1007/S10729-005-0399-1
Sarah C Stallings, Dan Huse, Stan N Finkelstein, William H Crown, Whitney P Witt, Jon Maguire, Arthur J Hiller, Anthony J Sinskey, Geoffrey S Ginsburg, A framework to evaluate the economic impact of pharmacogenomics Pharmacogenomics. ,vol. 7, pp. 853- 862 ,(2006) , 10.2217/14622416.7.6.853
Tom Cox, Jack Cuzick, HPV DNA testing in cervical cancer screening: from evidence to policies. Gynecologic Oncology. ,vol. 103, pp. 8- 11 ,(2006) , 10.1016/J.YGYNO.2006.07.030
Ren??e J. Goldberg Arnold, Ren??e Kim, Boxiong Tang, The cost-effectiveness of argatroban treatment in heparin-induced thrombocytopenia: the effect of early versus delayed treatment. Cardiology in Review. ,vol. 14, pp. 7- 13 ,(2006) , 10.1097/01.CRD.0000164011.17381.6F
Renée J. Goldberg Arnold, Cost-effectiveness analysis: should it be required for drug registration and beyond? Drug Discovery Today. ,vol. 12, pp. 960- 965 ,(2007) , 10.1016/J.DRUDIS.2007.09.010